Literature DB >> 6942429

Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA.

P P Major, E M Egan, G P Beardsley, M D Minden, D W Kufe.   

Abstract

We recently demonstrated a highly significant relationship between the incorporation of 1-beta-D-arabinofuranosylcytosine (ara-C) into L1210 DNA and the loss of clonogenic survival. These studies have now been extended to the human promyeloblast (HL-60) cell line and myeloblasts from a patient with acute myelogenous leukemia. Our results demonstrate: (i) the specific internucleotide incorporation of ara-C into human myeloblast DNA; (ii) the lability of [3H]ara-C-labeled DNA to alkali which necessitates the use of nondegrading assay conditions; and (iii) a highly significant relationship (P less than 0.0001) between the loss of clonogenicity of these cells and the extent of ara-C incorporation. These findings suggest that the incorporation of ara-C into DNA is one of the initial events leading to cell lethality. This method is applicable to clinical samples of bone marrow and peripheral blood as an in vitro assay for studying the sensitivity of cell populations to this drug.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6942429      PMCID: PMC319536          DOI: 10.1073/pnas.78.5.3235

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  18 in total

Review 1.  The mechanism of action of inhibitors of DNA synthesis.

Authors:  N R Cozzarelli
Journal:  Annu Rev Biochem       Date:  1977       Impact factor: 23.643

2.  Kinetic and template studies with 1- -D-arabinofuranosylcytosine 5'-triphosphate and mammalian deoxyribonucleic acid polymerase.

Authors:  R L Momparler
Journal:  Mol Pharmacol       Date:  1972-05       Impact factor: 4.436

3.  Action of 1- -D-arabinofuranosylcytosine on mammalian tumor cells. 1. Incorporation into DNA.

Authors:  R K Zahn; W E Müller; W Forster; A Maidhof; R Beyer
Journal:  Eur J Cancer       Date:  1972-08       Impact factor: 9.162

4.  Inhibition of DNA synthesis but not of poly-dAT synthesis by the arabinose analogue of cytidine in vitro.

Authors:  N B Furlong; C Gresham
Journal:  Nature       Date:  1971-10-13       Impact factor: 49.962

5.  The incorporation of 3H-cytosine arabinoside and its effect on murine leukemic cells (L5178Y).

Authors:  M Y Chu; G A Fischer
Journal:  Biochem Pharmacol       Date:  1968-05       Impact factor: 5.858

6.  The effect of-beta-D-arabinofuranosylcytosine on growth, viability, and DNA synthesis of mouse L-cells.

Authors:  F L Graham; G F Whitmore
Journal:  Cancer Res       Date:  1970-11       Impact factor: 12.701

7.  Studies in mouse L-cells on the incorporation of 1-beta-D-arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by 1-beta-D-arabinofuranosylcytosine 5'-triphosphate.

Authors:  F L Graham; G F Whitmore
Journal:  Cancer Res       Date:  1970-11       Impact factor: 12.701

8.  Dose schedule and antitumor studies of arabinosyl cytosine (NSC 63878).

Authors:  E Frei; J N Bickers; J S Hewlett; M Lane; W V Leary; R W Talley
Journal:  Cancer Res       Date:  1969-07       Impact factor: 12.701

9.  Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and response to therapy.

Authors:  Y M Rustum; H D Preisler
Journal:  Cancer Res       Date:  1979-01       Impact factor: 12.701

10.  Inhibition of mammalian DNA polymerase by the 5'-triphosphate of 1-beta-d-arabinofuranosylcytosine and the 5'-triphosphate of 9-beta-d-arabinofuranoxyladenine.

Authors:  J J Furth; S S Cohen
Journal:  Cancer Res       Date:  1968-10       Impact factor: 12.701

View more
  42 in total

1.  Mechanistic implications of alterations in HL-60 cell nascent DNA after exposure to 1-beta-D-arabinofuranosylcytosine.

Authors:  D D Ross; D P Cuddy; N Cohen; D R Hensley
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Cellular pharmacology of 1-beta-D-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells.

Authors:  R L Momparler; N Onetto-Pothier; D Y Bouffard; L F Momparler
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 3.  Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.

Authors:  W Hiddemann
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

Review 4.  A comparison of the effects of cytosine arabinoside and beta-lactams on DNA synthesis and cellular proliferation.

Authors:  R J Fram
Journal:  Cell Biol Toxicol       Date:  1986-12       Impact factor: 6.691

5.  Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing.

Authors:  Tiffany M Scharadin; Michael A Malfatti; Kurt Haack; Kenneth W Turteltaub; Chong-Xian Pan; Paul T Henderson; Brian A Jonas
Journal:  Chem Res Toxicol       Date:  2018-09-10       Impact factor: 3.739

6.  The effect of ara-C-induced inhibition of DNA synthesis on its cellular pharmacology.

Authors:  L M Wang; J C White; R L Capizzi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

7.  Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.

Authors:  Judith E Karp; Brian M Thomas; Jacqueline M Greer; Christopher Sorge; Steven D Gore; Keith W Pratz; B Douglas Smith; Karen S Flatten; Kevin Peterson; Paula Schneider; Karen Mackey; Tomoko Freshwater; Mark J Levis; Michael A McDevitt; Hetty E Carraway; Douglas E Gladstone; Margaret M Showel; Sabine Loechner; David A Parry; Jo Ann Horowitz; Randi Isaacs; Scott H Kaufmann
Journal:  Clin Cancer Res       Date:  2012-10-23       Impact factor: 12.531

8.  Comparative study of autophagy inhibition by 3MA and CQ on Cytarabine‑induced death of leukaemia cells.

Authors:  Caroline Palmeira dos Santos; Gustavo J S Pereira; Christiano M V Barbosa; Aron Jurkiewicz; Soraya S Smaili; Claudia Bincoletto
Journal:  J Cancer Res Clin Oncol       Date:  2014-06       Impact factor: 4.553

9.  Enhanced retention of cytosine arabinoside and its metabolites and synergistic cytotoxicity by sequential treatment with dipyridamole in L5178Y leukemia.

Authors:  J L Yang; J C White; R L Capizzi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

10.  Chemical synthesis of DNA oligomers containing cytosine arabinoside.

Authors:  G P Beardsley; T Mikita; M M Klaus; A L Nussbaum
Journal:  Nucleic Acids Res       Date:  1988-10-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.